For this reason and many aforementioned benefits above, we recommend fitting the tumor burden dynamic model to both the conventional continuous metric (e.g. M-protein levels in g/dL) and the continuous MRD metric (e.g. number of cancer cells per ml of sample) simultaneously, which provides greater identifiability particularly when M-protein is below the limit of quantitation (BLQ), which is often the only time MRD is assessed [127]. This evidence concerns the gene MYOM2 and cancer.